Subsequent Events	3 Months Ended
Mar. 31, 2024
Subsequent Events
Subsequent Events	15. Subsequent Events December 2021 ATM Agreement From April 1, 2024 to May 14, 2024, the Company issued an aggregate of 19,863,548 shares of common stock under the December 2021 ATM Agreement for total net proceeds of $2.2 million. April 2024 Agreement for Gelclair As part of the Company’s strategy to expand the commercial footprint beyond HIV-related supportive care to include cancer-related supportive care, on April 12, 2024, the Company entered into an exclusive 5-year in-license agreement with United Kingdom-based Venture Life Group PLC ("Venture Life"), an international consumer health company focused on the global self-care market for Venture Life's FDA-approved oral mucositis prescription product, Gelclair for the U.S. market. The Company is planning to begin commercial launch in the third quarter of 2024 for Gelclair. Submission of Matters to a Vote of Security Holders On April 9, 2024, the Company held a special meeting of stockholders of the Company (the “Special Meeting”). Four proposals were submitted to and approved by the Company’s stockholders, each of which is described in the Company’s definitive proxy statement for the Special Meeting (the “Proxy Statement”), filed with the Securities and Exchange Commission on March 15, 2024

Subsequent Events

3 Months Ended

Mar. 31, 2024

15. Subsequent Events

December 2021 ATM Agreement

From April 1, 2024 to May 14, 2024, the Company issued an aggregate of 19,863,548 shares of common stock under the December 2021 ATM Agreement for total net proceeds of $2.2 million.

April 2024 Agreement for Gelclair

As part of the Company’s strategy to expand the commercial footprint beyond HIV-related supportive care to include cancer-related supportive care, on April 12, 2024, the Company entered into an exclusive 5-year in-license agreement with United Kingdom-based Venture Life Group PLC ("Venture Life"), an international consumer health company focused on the global self-care market for Venture Life's FDA-approved oral mucositis prescription product, Gelclair for the U.S. market. The Company is planning to begin commercial launch in the third quarter of 2024 for Gelclair.

Submission of Matters to a Vote of Security Holders

On April 9, 2024, the Company held a special meeting of stockholders of the Company (the “Special Meeting”). Four proposals were submitted to and approved by the Company’s stockholders, each of which is described in the Company’s definitive proxy statement for the Special Meeting (the “Proxy Statement”), filed with the Securities and Exchange Commission on March 15, 2024